All News

A practical, evidence-based overview of how to recognize hidradenitis suppurativa early, stage disease severity, and coordinate care before progression.

Gilead's ARTISTRY-2 trial shows a promising single-tablet HIV treatment regimen is noninferior to standard therapy, expanding options for virologically suppressed adults.

The mobile-based program targets cognitive processes underlying attention and is intended for use alongside medication, therapy, or education.

Missed endpoints in midstage tau trials are reshaping the Alzheimer pipeline, with growing focus on inflammatory and vascular pathways. Review them here.

CGM users experienced fewer ED and inpatient days and better glycemic outcomes, but most eligible adults in this large cohort did not use the technology.

Dupilumab shows superior 2-year drug survival rates in atopic dermatitis compared to other biologics and JAK inhibitors, highlighting its effectiveness in treatment persistence.

Phase 3 results showed durable conversion benefits with a favorable safety profile, informing real-world management of acute PSVT outside of emergency settings.

A population-based study finds stimulant prescribing accelerated after 2020, with the largest increases among adults and women.

Zolifodacin is a single-dose oral treatment option for uncomplicated urogenital gonorrhea and one of the first new classes of drugs for the disease in 20 years.